A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...
The Estimates data displayed by Moneycontrol is not a recommendation to buy or sell any securities. Estimates data is a third party aggregated data provided by S&P Global Market Intelligence LLC for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback